TriangleNCT01841021 · REGISTRY CONDITION SEARCH
Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30
Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.
- Phase
- NA
- Status at capture
- TERMINATED
- Registry last update
- 2017-01-19
The main purpose of this study is to test if brentuximab vedotin has an effect on cancer in patients with a certain type of large B-cell lymphoma. The side effects (unwanted effects) of SGN-35 in patients with this certain type of large B-cell lymphoma will also be studied. It is not known if brentuximab vedotin is better or worse than other treatment patients might be given.
Open the original ClinicalTrials.gov record → · Download preserved record
What did the study report?
Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.
Participant flow
Baseline characteristics
Overall Response Rate (ORR)
Time to Response (TTR)
Duration of Response (DOR)
Time to Disease Progression (TTP)
Progression Free Survival (PFS)
Overall Survival (OS)
Number of Participants With Study Related Serious Adverse Events (SAEs)
Adverse events
Limitations, agreements, and source contact
Who could take part
- eligibility Criteria
- Inclusion Criteria: * Confirmed diagnosis of PTCL expressing CD30 receptor. Following PTCL subtypes will be eligible: Peripheral T - cell lymphoma, not otherwise specified (NOS); Angioimmunoblastic T-cell Lymphoma; Subcutaneous Panniculitis Like T-cell Lymphoma; Hepatosplenic gamma/delta T cell Lymphoma; Extranodal natural killer (NK)T-cell Lymphoma, nasal type; Enteropathy-associated T-cell lymphoma; Adult T-cell Leukemia/lymphoma; T-cell prolymphocytic leukemia; Primary cutaneous gamma-delta T-cell lymphoma; Aggressive NK cell leukemia; Aggressive subtype of T cell Large Granular Lymphocytic (LGL) or transformed LGL leukemia; Epstein Barr Virus(EBV)-positive T-cell lymphoproliferative disorders of childhood; Transformed mycosis fungoides who have progressed following treatment with at least one systemic therapy; Sezary syndrome * Histology slides and pathology material must be available at the site for each patient before enrollment in order to be sent to the Leading Institution of the study for central pathology review and pharmacodynamic studies. * Patients must have progressive, relapsed or refractory disease after: At least one prior systemic anti-lymphoma regimen (chemotherapy or immunotherapy except for transformed mycosis fungoides as described previously); Relapsed or failed autologous or allogeneic stem cell transplant. * Understand and voluntarily sign an Institutional Review Board (IRB) approved informed consent form * Must have at least one site of disease (index lesion) measurable in two dimensions by computed tomography (CT) * Patients with leukemic form of PTCL who will not have a measurable lesion in two dimensions by CT scan, relapsed or refractory disease must be detected by immunohistochemistry or flow cytometry and molecular clonality studies in bone marrow or peripheral blood. * At least 2 weeks since the last chemotherapy, radiation therapy, immunotherapy or any investigational products * Must meet the following criteria within 4 days before the first dose of study drug: * Neutrophils ≥1,000/ul * Hemoglobin ≥ 8 g/dL * Platelets≥ 50.0x10\^9 /L * Total bilirubin ≤ 1.5 x upper normal limit, or ≤ 5 x upper normal limit if documented hepatic involvement with lymphoma or history of Gilbert's Syndrome * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 x upper normal limit (≤ 5 x upper normal limit if documented hepatic involvement with lymphoma) * Calculated creatinine clearance ≥ 40 mL/min/1.73 m\^2 based on Cockcroft and Gault method * PT or International Normalization Ratio (INR), and Activated Partial Thromboplastin Time (APTT) ≤ 1.5 x upper limit of normal unless patient is receiving anticoagulants. If patient is on anticoagulation therapy, levels should be within therapeutic range. * Eastern Cooperative Oncology Group (ECOG) performance status 0-2 * Negative pregnancy test for women of childbearing potential * Recovered (≤ Grade 1 toxicity) from the reversible effects of prior antineoplastic therapy Exclusion Criteria: * Any of the following cardiovascular conditions or values within 6 months before the first dose of study drug: Myocardial infarction and the New York Heart Association (NYHA) Class III or IV heart failure * History of another primary malignancy not in clinical remission; except adequately treated patients with completely resected in situ carcinoma, such as nonmelanoma skin cancer and cervical carcinoma in situ on biopsy or a squamous intraepithelial lesion on Pap smear, or localized prostate cancer with prostate-specific antigen (PSA) \<1 ng/ml * Known active cerebral/meningeal involvement with lymphoma. Asymptomatic patients with previously treated and resolved central nervous system (CNS) lymphoma involvement are permitted. * Prior administration of Brentuximab vedotin * Corticosteroid monotherapy for lymphoma within 1 week of the first dose of study drug * Any serious underlying medical condition that, in the opinion of the investigator or medical monitor, would impair the ability to receive or tolerate the planned treatment * Known hypersensitivity to recombinant proteins, or any component contained in the drug formulation * Female patients who are lactating or have a positive serum pregnancy test during the screening period
- healthy Volunteers
- false
- minimum Age
- 18 Years
- sex
- ALL
- std Ages
- ADULT
- OLDER_ADULT
Treatment arms and interventions
- arm Groups
- description
- Brentuximab vedotin will be given intravenously with a dose of 1.8 mg/kg every 21 days, over 30 minutes for 16 cycles in the clinic.
- intervention Names
- Drug: Brentuximab vedotin
- label
- Brentuximab Vedotin Treatment
- type
- EXPERIMENTAL
- interventions
- arm Group Labels
- Brentuximab Vedotin Treatment
- description
- Brentuximab vedotin will be given by intravenous infusion (into a vein) on Day 1 of every 21 day cycle.
- name
- Brentuximab vedotin
- other Names
- SGN-35
- ADCETRISTM
- antibody drug conjugate(ADC)
- chemotherapy
- monomethyl auristatin E (MMAE)
- type
- DRUG
Study design
- allocation
- NA
- intervention Model
- SINGLE_GROUP
- masking Info
- masking
- NONE
- primary Purpose
- TREATMENT
Enrollment
- count
- 1
- type
- ACTUAL
Registered outcome plans (not posted results)
- primary Outcomes
- description
- ORR: The proportion of patients with complete response (CR) and partial response (PR). Follow-up assessments after cycle 16 to be done every 12 weeks for up to 24 months. Restaging imaging computed tomography (CT) scans to be repeated 12 and 24 months from the beginning of the follow-up period. Objective disease response (CR and PR) defined according to the modified 2007 International Working Group (IWG) response criteria for non-Hodgkin lymphomas (NHL). CR = Disappearance of all evidence of disease; PR = Regression of measurable disease and no new sites.
- measure
- Overall Response Rate (ORR)
- time Frame
- Up to 24 months post treatment
- secondary Outcomes
- description
- Investigators intended to report median time and its 95% confidence interval estimate using the Kaplan-Meier method, for 20 participants. TTR: The time from the start of treatment to the first time when the measurement criteria for CR or PR are met. Participants who did not have a confirmed response to be censored at the date of the last tumor assessment.
- measure
- Time to Response (TTR)
- time Frame
- Up to 24 months post treatment
- description
- DOR: The number of days between the first tumor response assessment of objective response (complete response and partial response) to the time of the first tumor response assessment of progressive disease (PD) or death if due to disease progression (date of first PD assessment or death due to disease progression-date of first objective response assessment +1).
- measure
- Duration of Response (DOR)
- time Frame
- Up to 24 months post treatment
- description
- Investigators intended to report median time and its 95% confidence interval estimate using the Kaplan-Meier method, for 20 participants. Progressive disease (PD) defined according to the modified 2007 International Working Group (IWG) response criteria for non-Hodgkin lymphomas (NHL).
- measure
- Time to Disease Progression (TTP)
- time Frame
- Up to 24 months post treatment
- description
- Investigators intended to report median time and its 95% confidence interval estimate using the Kaplan-Meier method, for 20 participants. Stable disease (SD) defined according to the modified 2007 International Working Group (IWG) response criteria for non-Hodgkin lymphomas (NHL).
- measure
- Progression Free Survival (PFS)
- time Frame
- 24 months post treatment
- description
- Investigators intended to report median time and its 95% confidence interval estimate using the Kaplan-Meier method, for 20 participants. Radiological assessments to be discontinued at the time of tumor progression or initiation of new anticancer therapy, after which survival to be evaluated every 3 months until 2 years from the start of study treatment or until study closure.
- measure
- Overall Survival (OS)
- time Frame
- 24 months post treatment or until study closure
- description
- Serious adverse events (SAEs) to be summarized by worst NCI NCI Common Terminology Criteria for Adverse Events (CTCAE) grade.
- measure
- Number of Participants With Study Related Serious Adverse Events (SAEs)
- time Frame
- Up to 24 months post treatment
Full study description
- brief Summary
- The main purpose of this study is to test if brentuximab vedotin has an effect on cancer in patients with a certain type of large B-cell lymphoma. The side effects (unwanted effects) of SGN-35 in patients with this certain type of large B-cell lymphoma will also be studied. It is not known if brentuximab vedotin is better or worse than other treatment patients might be given.
Source references
Source notices and limitations
Discovery and provenance
- release id
- ctgov-registry-1336d216cbd1bbff780dac70
- edge id
- nct-edge-6c01a2c6408384d4a18e
- requested nct id
- NCT01841021
- primary nct id
- NCT01841021
- source kind
- ctgov_condition_query
- source record id
- Source null
- source file sha256
- e270600534699a676fe83226e7a7b0f73aeb00c1d0a05cfc115c748864ad8173
- payload sha256
- 1fe3824a48080718283bdcccdb0531d38d9c8de5b9ef2442e9e8c364b65689bb
- payload
- clinical indication matching status
- condition_index_match_asserted_by_registry_not_reviewed
- end exclusive
- true
- id
- nct-edge-6c01a2c6408384d4a18e
- link basis
- returned_by_explicit_condition_and_posted_results_filter_query
- nct id
- NCT01841021
- occurrences
- context exact
- NCT01841021
- end
- 11
- exact text
- NCT01841021
- start
- 0
- offset unit
- unicode_code_points
- query cond
- Peripheral T-Cell Non-Hodgkin Lymphoma
- query disease state id
- ds-peripheral-t-cell-non-hodgkin-lymphoma
- source file
- /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-peripheral-t-cell-non-hodgkin-lymphoma-000.json
- source file sha256
- e270600534699a676fe83226e7a7b0f73aeb00c1d0a05cfc115c748864ad8173
- source json pointer
- /studies/13/protocolSection/identificationModule/nctId
- source kind
- ctgov_condition_query
- source record id
- Source null
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- 834cb118fdcdd4185141fc04c8dcf8c4773f330447b2085019de361d7b85ba61
Preserved source evidence · Not medical advice